COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway

Aberrant activation of the mitogen-activated protein kinase (MAPK) cascade promotes oncogenic transcriptomes. Despite efforts to inhibit oncogenic kinases, such as BRAFV600E, tumor responses in patients can be heterogeneous and limited by drug resistance mechanisms. Here, we describe patient tumors...

Full description

Saved in:
Bibliographic Details
Main Authors: Ada Ndoja, Christopher M. Rose, Eva Lin, Rohit Reja, Jelena Petrovic, Sarah Kummerfeld, Andrew Blair, Helen Rizos, Zora Modrusan, Scott Martin, Donald S. Kirkpatrick, Amy Heidersbach, Tao Sun, Benjamin Haley, Ozge Karayel, Kim Newton, Vishva M. Dixit
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Cells
Subjects:
COP1
DET1
BRAF
melanoma
vemurafenib
Online Access:https://www.mdpi.com/2073-4409/14/13/975
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/2073-4409/14/13/975

Similar Items